查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1889520

2025年下一代癌症诊断全球市场报告

Next Generation Cancer Diagnostics Global Market Report 2025
出版日期: | 出版商: The Business Research Company | 英文 250 Pages | 商品交期: 2-10个工作天内

价格
简介目录

近年来，下一代癌症诊断市场发展迅速，预计将从2024年的127.1亿美元成长到2025年的144亿美元，复合年增长率达13.3%。过去几年的增长可归因于全球癌症发病率的上升、分子诊断技术的日益普及、对癌症早期检测需求的增长、医疗基础设施的扩张以及基于生物标誌物的筛检的日益普及。

预计未来几年，下一代癌症诊断市场将快速成长，到2029年市场规模将达到234.5亿美元，复合年增长率（CAGR）为13.0%。预测期内的成长预计将受到以下因素的推动：对精准肿瘤学的日益重视、对微创诊断技术需求的增长、人工智慧和数位工具在癌症检测中的应用日益广泛、基因组检测服务的扩展以及政府对癌症研究投入的增加。预测期内的关键趋势包括：非侵入性诊断检测方法的开发、云端基础的数据分析的整合、基于奈米技术的生物感测器的创新、真实世界数据和临床数据的整合以及机器人和自动化技术的整合。

未来几年，对个人化医疗日益增长的需求预计将推动下一代癌症诊断市场的扩张。个人化医疗是指根据个人的基因组成、生活方式和环境量身定制治疗方法，以确保每位患者都能获得最有效的治疗方法。这种需求的驱动力源于慢性病和罕见患者病率的不断上升，这些疾病需要针对特定患者进行标靶治疗，以获得更好的临床疗效。下一代癌症诊断技术透过提供精准的分子讯息，为个人化医疗提供支持，从而根据患者独特的基因和肿瘤特征制定个人化的治疗策略。例如，根据美国非营利组织「个人化医疗联盟」（Personalized Medicine Coalition）2024年2月发布的报告，美国食品药物管理局（FDA）预计将在2023年核准16种针对罕见疾病患者的新型个人化疗法，较2022年的6种显着增加。因此，对个人化医疗日益增长的需求正在推动下一代癌症诊断市场的成长。

新一代癌症诊断市场的主要企业正在开发创新解决方案，例如人工智慧 (AI) 驱动的多模态诊断平台，以实现早期检测、个人化治疗和改进临床决策。这些 AI 驱动的多模态平台整合并分析包括基因组、蛋白质组、影像和临床资讯在内的多种生物学数据，从而实现更精准、更个人化的癌症检测和诊断。例如，2025 年 4 月，总部位于印度的精准肿瘤学公司 OneCell Diagnostics Pvt Ltd. 推出了 OncoIncytes，多模态癌症诊断平台。该平台整合了循环肿瘤 DNA、单细胞循环性肿瘤细胞、RNA 数据以及 150 种蛋白质的单细胞层面详细图谱。 OncoIncytes 利用 AI 和机器学习驱动的包含 1080 个基因的 panel，提供高度灵敏和特异性的分析结果，可以改善临床试验结果，尤其是在早期研究和抗体药物复合体(ADC) 开发方面。该平台透过非侵入性、即时和可扩展的诊断技术，支援个人化癌症检测、治疗监测和药物开发，所有这些技术都可透过 OneCell 的专有 iDiscover 应用程式提供给 CLIA 认证的检查室。

目录

第一章执行摘要

第二章 市场特征

第三章 市场趋势与策略

第四章 市场：宏观经济情景，包括利率、通货膨胀、地缘政治、贸易战和关税，以及新冠疫情及其復苏对市场的影响

第五章 全球成长分析与策略分析框架

  • 全球下一代癌症诊断市场：PESTEL 分析（政治、社会、技术、环境、法律因素、驱动因素和限制因素）
  • 终端用户产业分析
  • 全球下一代癌症诊断市场：成长率分析
  • 全球下一代癌症诊断市场表现：规模与成长，2019-2024年
  • 全球下一代癌症诊断市场预测：规模和成长，2024-2029年，2034年预测
  • 全球下一代癌症诊断市场：潜在市场规模 (TAM)

第六章 市场细分

  • 全球下一代癌症诊断市场：依技术、效能和预测划分，2019-2024年、2024-2029年预测、2034年预测
  • 次世代定序（NGS）
  • Q聚合酵素链锁反应与多重反应
  • 晶片实验室（LOAC）和逆转录聚合酵素链锁反应（RT-PCR）
  • 循环肿瘤DNA检测
  • 蛋白质微阵列
  • 去氧核糖核酸微阵列
  • 其他多组体学平台
  • 全球下一代癌症诊断市场：按癌症类型、表现和预测划分，2019-2024年、2024-2029年预测、2034年预测
  • 肺癌
  • 乳癌
  • 大肠直肠癌
  • 子宫颈癌
  • 全球下一代癌症诊断市场：依功能、效能和预测划分，2019-2024年、2024-2029年预测、2034年预测
  • 治疗监测
  • 伴随诊断
  • 预后诊断
  • 癌症筛检
  • 风险分析
  • 全球下一代癌症诊断市场：按应用、效能和预测划分，2019-2024年、2024-2029年预测、2034年预测
  • 生物标誌物开发
  • 循环性肿瘤细胞（CTC）分析
  • 蛋白质体学分析
  • 表观遗传分析
  • 基因分析
  • 全球下一代癌症诊断市场：依最终用户、效能和预测划分，2019-2024年、2024-2029年预测、2034年预测
  • 医院和诊所
  • 诊断检查室
  • 研究和学术机构
  • 製药和生物技术公司
  • 居家医疗环境
  • 全球新一代癌症诊断市场：次世代定序细分，依类型、效能与预测（2019-2024年、2024-2029年预测、2034年预测）。
  • 全基因测序
  • 标靶基因定序
  • EXOME定序
  • 转录定序
  • 全球下一代癌症诊断市场：按聚合酵素链锁反应和多重检测技术细分，按类型划分，实际值和预测值，2019-2024年，2024-2029年预测值，2034年预测值
  • 定量聚合酵素链锁反应
  • 数位聚合酵素链锁反应
  • 多重聚合酵素链锁反应
  • 逆转录聚合酵素链锁反应
  • 全球下一代癌症诊断市场：按晶片实验室和逆转录-聚合酵素链锁反应细分，按类型、性能和预测（2019-2024年、2024-2029年预测、2034年预测）
  • 微流体晶片检测
  • 整合式逆转录聚合酵素链锁反应晶片
  • 照护现场实验室晶片设备
  • 高通量晶片实验室系统
  • 全球下一代癌症诊断市场：按循环肿瘤DNA检测方法细分，按类型、性能和预测（2019-2024年、2024-2029年预测、2034年预测）。
  • 单基因循环肿瘤去氧核糖核酸检测
  • 多基因循环肿瘤去氧核糖核酸检测
  • 数位液滴循环肿瘤DNA检测
  • 次世代定序循环肿瘤DNA检测
  • 全球下一代癌症诊断市场：按蛋白质微阵列、类型、性能和预测进行细分，2019-2024年、2024-2029年预测、2034年预测
  • 分析型蛋白质微阵列
  • 功能性蛋白质微阵列
  • 反相蛋白质微阵列
  • 基于抗体的蛋白质微阵列
  • 全球下一代癌症诊断市场：去氧核糖核酸微阵列细分，按类型、性能和预测（2019-2024年、2024-2029年预测、2034年预测）
  • 基因表现去氧核糖核酸微阵列
  • 单核苷酸基因型鉴定去氧核糖核酸微阵列
  • 比较基因组杂合反应去氧核糖核酸微阵列
  • 甲基化去氧核糖核酸微阵列
  • 全球下一代癌症诊断市场：按其他多组体学平台细分，按类型、性能和预测（2019-2024年、2024-2029年预测、2034年预测）。
  • 代谢体学平台
  • 表观基因平台
  • 转录组学平台
  • 整合多组体学系统

第七章 区域和国家分析

  • 全球下一代癌症诊断市场：按地区、绩效和预测划分，2019-2024年、2024-2029年预测、2034年预测
  • 全球下一代癌症诊断市场：按国家、绩效和预测划分，2019-2024 年、2024-2029 年预测、2034 年预测

第八章 亚太市场

第九章：中国市场

第十章 印度市场

第十一章 日本市场

第十二章：澳洲市场

第十三章 印尼市场

第十四章 韩国市场

第十五章 西欧市场

第十六章英国市场

第十七章：德国市场

第十八章：法国市场

第十九章：义大利市场

第二十章：西班牙市场

第21章 东欧市场

第22章 俄罗斯市场

第23章 北美市场

第24章美国市场

第25章：加拿大市场

第26章 南美洲市场

第27章：巴西市场

第28章 中东市场

第29章：非洲市场

第三十章：竞争格局与公司概况

  • 下一代癌症诊断市场：竞争格局
  • 下一代癌症诊断市场：公司概况
    • F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
    • Novartis AG Overview, Products and Services, Strategy and Financial Analysis
    • Thermo Fisher Scientific Inc. Overview, Products and Services, Strategy and Financial Analysis
    • Abbott Laboratories Inc. Overview, Products and Services, Strategy and Financial Analysis
    • Siemens Healthineers AG Overview, Products and Services, Strategy and Financial Analysis

第31章：其他领先和创新企业

  • Danaher Corporation
  • Koninklijke Philips NV
  • General Electric Company
  • Becton, Dickinson and Company
  • Agilent Technologies Inc.
  • Illumina Inc.
  • Sysmex Corporation
  • Bio-Rad Laboratories Inc.
  • Exact Sciences Corporation
  • QIAGEN NV
  • Almac Group Ltd.
  • Natera Inc.
  • Myriad Genetics Inc.
  • NeoGenomics Inc.
  • Guardant Health Inc.

第32章 全球市场竞争基准化分析与仪錶板

第33章 重大併购

第34章 近期市场趋势

第35章：高潜力市场国家、细分市场与策略

  • 2029年下一代癌症诊断市场：提供新机会的国家
  • 2029年下一代癌症诊断市场：蕴藏新机会的细分市场
  • 下一代癌症诊断市场（2029 年）：成长策略
    • 基于市场趋势的策略
    • 竞争对手策略

第36章附录

简介目录
Product Code: r40068

Next generation cancer diagnostics refers to advanced diagnostic technologies that enable precise detection, characterization, and monitoring of cancer at the molecular and genetic levels. These diagnostics use cutting-edge tools such as genomics, proteomics, and liquid biopsy to support early detection, personalized treatment planning, and improved patient outcomes.

The main technologies used in next generation cancer diagnostics include next-generation sequencing (NGS), q-polymerase chain reaction and multiplexing, lab-on-a-chip (LOAC) and reverse transcriptase-polymerase chain reaction (RT-PCR), circulating tumor deoxyribonucleic acid (ctDNA) assays, protein microarrays, deoxyribonucleic acid microarrays, and others. Next-generation sequencing (NGS) is a high-throughput DNA sequencing method that enables rapid, simultaneous sequencing of millions of DNA fragments, allowing comprehensive analysis of genomes, transcriptomes, and genetic variations. These technologies target various cancer types, including lung cancer, breast cancer, colorectal cancer, and cervical cancer. Their functions include therapeutic monitoring, companion diagnostics, prognostics, cancer screening, and risk analysis. They are applied in biomarker development, circulating tumor cell (CTC) analysis, proteomic analysis, epigenetic analysis, and genetic analysis, and serve end users such as hospitals and clinics, diagnostic laboratories, research and academic institutions, pharmaceutical and biotechnology companies, and home care settings.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the healthcare sector, particularly in the supply of critical medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are facing higher costs for imported surgical instruments, imaging equipment, and consumables such as syringes and catheters, many of which have limited domestic alternatives. These increased costs are straining healthcare budgets, leading some providers to delay equipment upgrades or pass on expenses to patients. Additionally, tariffs on raw materials and components are disrupting the production of essential drugs and devices, causing supply chain bottlenecks. In response, the industry is diversifying sourcing strategies, boosting local manufacturing where possible, and advocating for tariff exemptions on life-saving medical products.

The next generation cancer diagnostics market research report is one of a series of new reports from The Business Research Company that provides next generation cancer diagnostics market statistics, including next generation cancer diagnostics industry global market size, regional shares, competitors with a next generation cancer diagnostics market share, detailed next generation cancer diagnostics market segments, market trends and opportunities, and any further data you may need to thrive in the next generation cancer diagnostics industry. This next generation cancer diagnostics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The next generation cancer diagnostics market size has grown rapidly in recent years. It will grow from $12.71 billion in 2024 to $14.40 billion in 2025 at a compound annual growth rate (CAGR) of 13.3%. The growth in the historic period resulted from the increasing prevalence of cancer worldwide, growing adoption of molecular diagnostics, rising demand for early cancer detection, expansion of healthcare infrastructure, and greater use of biomarker-based screening.

The next generation cancer diagnostics market size is expected to see rapid growth in the next few years. It will grow to $23.45 billion in 2029 at a compound annual growth rate (CAGR) of 13.0%. The growth in the forecast period will be driven by a rising focus on precision oncology, increasing demand for minimally invasive diagnostic techniques, growing adoption of artificial intelligence and digital tools in cancer detection, expansion of genomic testing services, and increasing government funding for cancer research. Major trends in the forecast period include the development of non-invasive diagnostic assays, integration of cloud-based data analytics, innovations in nanotechnology-based biosensors, incorporation of real-world evidence and clinical data, and the integration of robotics and automation.

The rising demand for personalized medicines is expected to drive the expansion of the next-generation cancer diagnostics market in the coming years. Personalized medicines are treatments tailored to an individual's genetic makeup, lifestyle, and environment to ensure the most effective therapy for each patient. This demand is fueled by the growing prevalence of chronic and rare diseases, which require targeted, patient-specific treatments for better clinical outcomes. Next-generation cancer diagnostics support personalized medicine by providing precise molecular insights that inform customized treatment strategies based on a patient's unique genetic and tumor profile. For example, in February 2024, the Personalized Medicine Coalition, a US-based non-profit organization, reported that the FDA approved 16 new personalized therapies for patients with rare diseases in 2023, a notable increase from six approvals in 2022. Consequently, the rising demand for personalized medicines is driving the growth of the next-generation cancer diagnostics market.

Key players in the next-generation cancer diagnostics market are developing innovative solutions such as artificial intelligence-driven multi-modal diagnostic platforms to improve early detection, personalized therapy, and clinical decision-making. These AI-powered multi-modal platforms integrate and analyze diverse biological data-including genomic, proteomic, imaging, and clinical information-to deliver more accurate and individualized cancer detection and diagnosis. For instance, in April 2025, OneCell Diagnostics Pvt Ltd., an India-based precision oncology company, launched OncoIncytes, a multi-modal cancer diagnostic platform designed for precision oncology. The platform combines circulating tumor DNA, single-cell circulating tumor cells, RNA data, and detailed protein profiles of 150 proteins at the single-cell level. Using a 1,080-gene panel powered by AI and machine learning, OncoIncytes provides highly sensitive and specific insights to improve clinical trial outcomes, particularly in early-stage research and antibody-drug conjugate development. The platform facilitates personalized cancer detection, therapy monitoring, and drug development through non-invasive, real-time, and scalable diagnostics, all accessible via OneCell's proprietary iDiscover application from a CLIA-certified laboratory.

In June 2023, Quest Diagnostics Inc., a US-based healthcare diagnostics company, acquired Haystack Oncology for an undisclosed amount. This acquisition aimed to strengthen Quest Diagnostics' capabilities in the rapidly growing minimal residual disease (MRD) liquid biopsy market. Haystack Oncology Inc., a US-based firm, provides next-generation cancer diagnostics through its tumor-informed MRD test, Haystack MRD.

Major companies operating in the next generation cancer diagnostics market are F. Hoffmann-La Roche AG, Novartis AG, Thermo Fisher Scientific Inc., Abbott Laboratories Inc., Siemens Healthineers AG, Danaher Corporation, Koninklijke Philips N.V., General Electric Company, Becton, Dickinson and Company, Agilent Technologies Inc., Illumina Inc., Sysmex Corporation, Bio-Rad Laboratories Inc., Exact Sciences Corporation, QIAGEN N.V., Almac Group Ltd., Natera Inc., Myriad Genetics Inc., NeoGenomics Inc., Guardant Health Inc., Freenome Holdings Inc., Personalis Inc., Burning Rock Biotech Limited., SOPHiA GENETICS S.A., Singlera Genomics Co. Ltd.

North America was the largest region in the next generation cancer diagnostics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in next generation cancer diagnostics report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the next generation cancer diagnostics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The next generation cancer diagnostics market consists of revenues earned by entities by providing services such as genomic and molecular profiling, liquid biopsy testing, next-generation sequencing (NGS) services, companion diagnostics development, and bioinformatics and data interpretation services. The market value includes the value of related goods sold by the service provider or included within the service offering. The next generation cancer diagnostics market also includes sales of gene panels, single-cell analysis systems, nanotechnology-based biosensors, molecular imaging agents, and exosome isolation kits. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Next Generation Cancer Diagnostics Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on next generation cancer diagnostics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
  • Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for next generation cancer diagnostics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The next generation cancer diagnostics market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

  • Markets Covered:1) By Technology: Next-Generation Sequencing (NGS); QPolymerase Chain Reaction And Multiplexing; Lab-On-A-Chip (LOAC) And Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR); Circulating Tumor Deoxyribonucleic Acid (ctDNA) Assays; Protein Microarrays; Deoxyribonucleic Acid Microarrays; Other Multi-Omics Platforms
  • 2) By Cancer Type: Lung Cancer; Breast Cancer; Colorectal Cancer; Cervical Cancer
  • 3) By Function: Therapeutic Monitoring; Companion Diagnostics; Prognostics; Cancer Screening; Risk Analysis
  • 4) By Application: Biomarker Development; Circulating Tumor Cell (CTC) Analysis; Proteomic Analysis; Epigenetic Analysis; Genetic Analysis
  • 5) By End User: Hospitals And Clinics; Diagnostic Laboratories; Research And Academic Institutions; Pharmaceutical And Biotechnology Companies; Home Care Settings
  • Subsegments:
  • 1) By Next-Generation Sequencing: Whole Genome Sequencing; Targeted Gene Sequencing; Exome Sequencing; Transcriptome Sequencing
  • 2) By Quantitative Polymerase Chain Reaction And Multiplexing: Quantitative Polymerase Chain Reaction; Digital Polymerase Chain Reaction; Multiplex Polymerase Chain Reaction; Reverse Transcription Polymerase Chain Reaction
  • 3) By Lab-On-A-Chip And Reverse Transcriptase-Polymerase Chain Reaction: Microfluidic Chip Assays; Integrated Reverse Transcriptase-Polymerase Chain Reaction Chips; Point-of-Care Lab-On-A-Chip Devices; High-Throughput Lab-On-A-Chip Systems
  • 4) By Circulating Tumor Deoxyribonucleic Acid Assays: Single-Gene Circulating Tumor Deoxyribonucleic Acid Assays; Multi-Gene Circulating Tumor Deoxyribonucleic Acid Panels; Digital Droplet Circulating Tumor Deoxyribonucleic Acid Assays; Next-Generation Sequencing Circulating Tumor Deoxyribonucleic Acid Assays
  • 5) By Protein Microarrays: Analytical Protein Microarrays; Functional Protein Microarrays; Reverse Phase Protein Microarrays; Antibody-Based Protein Microarrays
  • 6) By Deoxyribonucleic Acid Microarrays: Gene Expression Deoxyribonucleic Acid Microarrays; Single Nucleotide Polymorphism Genotyping Deoxyribonucleic Acid Microarrays; Comparative Genomic Hybridization Deoxyribonucleic Acid Microarrays; Methylation Deoxyribonucleic Acid Microarrays
  • 7) By Other Multi-Omics Platforms: Metabolomics Platforms; Epigenomics Platforms; Transcriptomics Platforms; Integrated Multi-Omics Systems
  • Companies Mentioned: F. Hoffmann-La Roche AG; Novartis AG; Thermo Fisher Scientific Inc.; Abbott Laboratories Inc.; Siemens Healthineers AG; Danaher Corporation; Koninklijke Philips N.V.; General Electric Company; Becton, Dickinson and Company; Agilent Technologies Inc.; Illumina Inc.; Sysmex Corporation; Bio-Rad Laboratories Inc.; Exact Sciences Corporation; QIAGEN N.V.; Almac Group Ltd.; Natera Inc.; Myriad Genetics Inc.; NeoGenomics Inc.; Guardant Health Inc.; Freenome Holdings Inc.; Personalis Inc.; Burning Rock Biotech Limited.; SOPHiA GENETICS S.A.; Singlera Genomics Co. Ltd.
  • Countries:

Table of Contents

1. Executive Summary

2. Next Generation Cancer Diagnostics Market Characteristics

3. Next Generation Cancer Diagnostics Market Trends And Strategies

4. Next Generation Cancer Diagnostics Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

  • 4.1. Supply Chain Impact from Tariff War & Trade Protectionism

5. Global Next Generation Cancer Diagnostics Growth Analysis And Strategic Analysis Framework

  • 5.1. Global Next Generation Cancer Diagnostics PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
  • 5.2. Analysis Of End Use Industries
  • 5.3. Global Next Generation Cancer Diagnostics Market Growth Rate Analysis
  • 5.4. Global Next Generation Cancer Diagnostics Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
  • 5.5. Global Next Generation Cancer Diagnostics Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
  • 5.6. Global Next Generation Cancer Diagnostics Total Addressable Market (TAM)

6. Next Generation Cancer Diagnostics Market Segmentation

  • 6.1. Global Next Generation Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Next-Generation Sequencing (NGS)
  • QPolymerase Chain Reaction And Multiplexing
  • Lab-On-A-Chip (LOAC) And Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR)
  • Circulating Tumor Deoxyribonucleic Acid (ctDNA) Assays
  • Protein Microarrays
  • Deoxyribonucleic Acid Microarrays
  • Other Multi-Omics Platforms
  • 6.2. Global Next Generation Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Lung Cancer
  • Breast Cancer
  • Colorectal Cancer
  • Cervical Cancer
  • 6.3. Global Next Generation Cancer Diagnostics Market, Segmentation By Function, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Therapeutic Monitoring
  • Companion Diagnostics
  • Prognostics
  • Cancer Screening
  • Risk Analysis
  • 6.4. Global Next Generation Cancer Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Biomarker Development
  • Circulating Tumor Cell (CTC) Analysis
  • Proteomic Analysis
  • Epigenetic Analysis
  • Genetic Analysis
  • 6.5. Global Next Generation Cancer Diagnostics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Hospitals And Clinics
  • Diagnostic Laboratories
  • Research And Academic Institutions
  • Pharmaceutical And Biotechnology Companies
  • Home Care Settings
  • 6.6. Global Next Generation Cancer Diagnostics Market, Sub-Segmentation Of Next-Generation Sequencing, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Whole Genome Sequencing
  • Targeted Gene Sequencing
  • Exome Sequencing
  • Transcriptome Sequencing
  • 6.7. Global Next Generation Cancer Diagnostics Market, Sub-Segmentation Of Quantitative Polymerase Chain Reaction And Multiplexing, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Quantitative Polymerase Chain Reaction
  • Digital Polymerase Chain Reaction
  • Multiplex Polymerase Chain Reaction
  • Reverse Transcription Polymerase Chain Reaction
  • 6.8. Global Next Generation Cancer Diagnostics Market, Sub-Segmentation Of Lab-On-A-Chip And Reverse Transcriptase-Polymerase Chain Reaction, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Microfluidic Chip Assays
  • Integrated Reverse Transcriptase-Polymerase Chain Reaction Chips
  • Point-of-Care Lab-On-A-Chip Devices
  • High-Throughput Lab-On-A-Chip Systems
  • 6.9. Global Next Generation Cancer Diagnostics Market, Sub-Segmentation Of Circulating Tumor Deoxyribonucleic Acid Assays, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Single-Gene Circulating Tumor Deoxyribonucleic Acid Assays
  • Multi-Gene Circulating Tumor Deoxyribonucleic Acid Panels
  • Digital Droplet Circulating Tumor Deoxyribonucleic Acid Assays
  • Next-Generation Sequencing Circulating Tumor Deoxyribonucleic Acid Assays
  • 6.10. Global Next Generation Cancer Diagnostics Market, Sub-Segmentation Of Protein Microarrays, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Analytical Protein Microarrays
  • Functional Protein Microarrays
  • Reverse Phase Protein Microarrays
  • Antibody-Based Protein Microarrays
  • 6.11. Global Next Generation Cancer Diagnostics Market, Sub-Segmentation Of Deoxyribonucleic Acid Microarrays, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Gene Expression Deoxyribonucleic Acid Microarrays
  • Single Nucleotide Polymorphism Genotyping Deoxyribonucleic Acid Microarrays
  • Comparative Genomic Hybridization Deoxyribonucleic Acid Microarrays
  • Methylation Deoxyribonucleic Acid Microarrays
  • 6.12. Global Next Generation Cancer Diagnostics Market, Sub-Segmentation Of Other Multi-Omics Platforms, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Metabolomics Platforms
  • Epigenomics Platforms
  • Transcriptomics Platforms
  • Integrated Multi-Omics Systems

7. Next Generation Cancer Diagnostics Market Regional And Country Analysis

  • 7.1. Global Next Generation Cancer Diagnostics Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 7.2. Global Next Generation Cancer Diagnostics Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Next Generation Cancer Diagnostics Market

  • 8.1. Asia-Pacific Next Generation Cancer Diagnostics Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Next Generation Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.3. Asia-Pacific Next Generation Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.4. Asia-Pacific Next Generation Cancer Diagnostics Market, Segmentation By Function, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Next Generation Cancer Diagnostics Market

  • 9.1. China Next Generation Cancer Diagnostics Market Overview
  • 9.2. China Next Generation Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.3. China Next Generation Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.4. China Next Generation Cancer Diagnostics Market, Segmentation By Function, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Next Generation Cancer Diagnostics Market

  • 10.1. India Next Generation Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.2. India Next Generation Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.3. India Next Generation Cancer Diagnostics Market, Segmentation By Function, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Next Generation Cancer Diagnostics Market

  • 11.1. Japan Next Generation Cancer Diagnostics Market Overview
  • 11.2. Japan Next Generation Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.3. Japan Next Generation Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.4. Japan Next Generation Cancer Diagnostics Market, Segmentation By Function, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Next Generation Cancer Diagnostics Market

  • 12.1. Australia Next Generation Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.2. Australia Next Generation Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.3. Australia Next Generation Cancer Diagnostics Market, Segmentation By Function, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Next Generation Cancer Diagnostics Market

  • 13.1. Indonesia Next Generation Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.2. Indonesia Next Generation Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.3. Indonesia Next Generation Cancer Diagnostics Market, Segmentation By Function, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Next Generation Cancer Diagnostics Market

  • 14.1. South Korea Next Generation Cancer Diagnostics Market Overview
  • 14.2. South Korea Next Generation Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.3. South Korea Next Generation Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.4. South Korea Next Generation Cancer Diagnostics Market, Segmentation By Function, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Next Generation Cancer Diagnostics Market

  • 15.1. Western Europe Next Generation Cancer Diagnostics Market Overview
  • 15.2. Western Europe Next Generation Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.3. Western Europe Next Generation Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.4. Western Europe Next Generation Cancer Diagnostics Market, Segmentation By Function, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Next Generation Cancer Diagnostics Market

  • 16.1. UK Next Generation Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.2. UK Next Generation Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.3. UK Next Generation Cancer Diagnostics Market, Segmentation By Function, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Next Generation Cancer Diagnostics Market

  • 17.1. Germany Next Generation Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.2. Germany Next Generation Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.3. Germany Next Generation Cancer Diagnostics Market, Segmentation By Function, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Next Generation Cancer Diagnostics Market

  • 18.1. France Next Generation Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.2. France Next Generation Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.3. France Next Generation Cancer Diagnostics Market, Segmentation By Function, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Next Generation Cancer Diagnostics Market

  • 19.1. Italy Next Generation Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.2. Italy Next Generation Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.3. Italy Next Generation Cancer Diagnostics Market, Segmentation By Function, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Next Generation Cancer Diagnostics Market

  • 20.1. Spain Next Generation Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.2. Spain Next Generation Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.3. Spain Next Generation Cancer Diagnostics Market, Segmentation By Function, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Next Generation Cancer Diagnostics Market

  • 21.1. Eastern Europe Next Generation Cancer Diagnostics Market Overview
  • 21.2. Eastern Europe Next Generation Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.3. Eastern Europe Next Generation Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.4. Eastern Europe Next Generation Cancer Diagnostics Market, Segmentation By Function, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Next Generation Cancer Diagnostics Market

  • 22.1. Russia Next Generation Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.2. Russia Next Generation Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.3. Russia Next Generation Cancer Diagnostics Market, Segmentation By Function, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Next Generation Cancer Diagnostics Market

  • 23.1. North America Next Generation Cancer Diagnostics Market Overview
  • 23.2. North America Next Generation Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.3. North America Next Generation Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.4. North America Next Generation Cancer Diagnostics Market, Segmentation By Function, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Next Generation Cancer Diagnostics Market

  • 24.1. USA Next Generation Cancer Diagnostics Market Overview
  • 24.2. USA Next Generation Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.3. USA Next Generation Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.4. USA Next Generation Cancer Diagnostics Market, Segmentation By Function, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Next Generation Cancer Diagnostics Market

  • 25.1. Canada Next Generation Cancer Diagnostics Market Overview
  • 25.2. Canada Next Generation Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.3. Canada Next Generation Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.4. Canada Next Generation Cancer Diagnostics Market, Segmentation By Function, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Next Generation Cancer Diagnostics Market

  • 26.1. South America Next Generation Cancer Diagnostics Market Overview
  • 26.2. South America Next Generation Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.3. South America Next Generation Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.4. South America Next Generation Cancer Diagnostics Market, Segmentation By Function, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Next Generation Cancer Diagnostics Market

  • 27.1. Brazil Next Generation Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.2. Brazil Next Generation Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.3. Brazil Next Generation Cancer Diagnostics Market, Segmentation By Function, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Next Generation Cancer Diagnostics Market

  • 28.1. Middle East Next Generation Cancer Diagnostics Market Overview
  • 28.2. Middle East Next Generation Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.3. Middle East Next Generation Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.4. Middle East Next Generation Cancer Diagnostics Market, Segmentation By Function, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Next Generation Cancer Diagnostics Market

  • 29.1. Africa Next Generation Cancer Diagnostics Market Overview
  • 29.2. Africa Next Generation Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.3. Africa Next Generation Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.4. Africa Next Generation Cancer Diagnostics Market, Segmentation By Function, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Next Generation Cancer Diagnostics Market Competitive Landscape And Company Profiles

  • 30.1. Next Generation Cancer Diagnostics Market Competitive Landscape
  • 30.2. Next Generation Cancer Diagnostics Market Company Profiles
    • 30.2.1. F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.2. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.3. Thermo Fisher Scientific Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.4. Abbott Laboratories Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.5. Siemens Healthineers AG Overview, Products and Services, Strategy and Financial Analysis

31. Next Generation Cancer Diagnostics Market Other Major And Innovative Companies

  • 31.1. Danaher Corporation
  • 31.2. Koninklijke Philips N.V.
  • 31.3. General Electric Company
  • 31.4. Becton, Dickinson and Company
  • 31.5. Agilent Technologies Inc.
  • 31.6. Illumina Inc.
  • 31.7. Sysmex Corporation
  • 31.8. Bio-Rad Laboratories Inc.
  • 31.9. Exact Sciences Corporation
  • 31.10. QIAGEN N.V.
  • 31.11. Almac Group Ltd.
  • 31.12. Natera Inc.
  • 31.13. Myriad Genetics Inc.
  • 31.14. NeoGenomics Inc.
  • 31.15. Guardant Health Inc.

32. Global Next Generation Cancer Diagnostics Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Next Generation Cancer Diagnostics Market

34. Recent Developments In The Next Generation Cancer Diagnostics Market

35. Next Generation Cancer Diagnostics Market High Potential Countries, Segments and Strategies

  • 35.1 Next Generation Cancer Diagnostics Market In 2029 - Countries Offering Most New Opportunities
  • 35.2 Next Generation Cancer Diagnostics Market In 2029 - Segments Offering Most New Opportunities
  • 35.3 Next Generation Cancer Diagnostics Market In 2029 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer